

PRESS RELEASE

Gradientech wins Clinical Diagnostics Campaign of the Year

Uppsala, Sweden, August 5, 2025. The diagnostics company Gradientech today announces to have been awarded the Clinical Diagnostics Campaign of the Year at the prestigious Scientists' Choice Awards® 2025, presented by SelectScience® during the ADLM 2025 (Association for Diagnostics & Laboratory Medicine) conference in Chicago, US.

The award recognises Gradientech's impactful and innovative campaign to raise awareness about its QuickMIC® ultra-rapid antibiotic susceptibility testing (AST) system, designed to support faster and smarter sepsis diagnostics. The winning campaign, produced in collaboration with SelectScience, featured infographics based on survey data from hundreds of laboratory professionals, webinars with key opinion leaders, event coverage, and targeted email communications - reaching a global clinical diagnostics audience.

"We are delighted and honoured," says AnnaLotta Schiller, Chief Commercial Officer of Gradientech. "We designed our QuickMIC campaign as a collaborative effort with leading clinicians in the sepsis diagnostics space. Like us, they strongly believe in the future of smarter, faster diagnostic solutions that have the potential to bring real clinical value to patients and help preserve the efficacy of antibiotics for generations to come."

The Scientists' Choice Awards, hosted annually by SelectScience, highlight excellence across the clinical and life science sectors. SelectScience is a globally recognised online platform providing peer-to-peer reviews and trusted scientific content to the global research and clinical community.

QuickMIC® and its gram-negative panel are CE marked and commercially available in Europe. QuickMIC is classified as a Breakthrough Device by the U.S. Food and Drug Administration and available for Investigational Use Only in the U.S., but not 510(k) cleared.

For further information, please contact:

Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se

About Gradientech

Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our innovative diagnostic solutions aim to save lives, reduce healthcare costs, and combat the spread of antibiotic resistance - one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.